PepGen Inc. (NASDAQ:PEPG) Financings
Financings
| Raise | Date |
|---|---|
| Public offering of common stock Update: US$125M · US$5 a share · Leerink Partners +4 Dealers: Leerink Partners (co-lead), Stifel (co-lead), Guggenheim Securities (co-lead), Oppenheimer & Co., H.C. Wainwright & Co. Use of proceeds: Fund ongoing clinical development of its product candidate, working capital and general corporate purposes | Nov 12, 2026 |
| Public offering of common stock Closed: US$115M raised · US$3.2 a share · Leerink Partners +1 Dealers: Leerink Partners (co-lead), Stifel (co-lead) Use of proceeds: Research and clinical development, including the FREEDOM-DM1 and FREEDOM2-DM1 trials, working capital and general corporate purposes | Sep 29, 2025 |